A treatment platform designed to activate endogenous anti-tumor immunity through integrated thermal physics and immunotherapeutic approaches. Combines multiple therapeutic modalities to enhance immune response against malignant tumors.
Manufactured by
Shanghai MAaGI Medical Technology Co., Ltd
China
Shanghai MAaGI Medical Technology was founded by a multidisciplinary medical engineering team from Shanghai Jiao Tong University with over 20 years of research in thermal-physical immunology. The company developed the world's first multimodal tumor treatment system, approved in 2023 through China's Innovative Medical Device Special Review Process. The system combines liquid nitrogen cryoablation with radiofrequency thermal therapy for solid tumor treatment while activating anti-tumor immune responses. Clinical validation completed at multiple top-tier hospitals including Fudan University Cancer Hospital and Ruijin Hospital.
© 2026 Suplivia · Home · Browse Products